ANA CUEBAS: Open Payments
NPI 1417277997 · FAYETTEVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,845 in 95 payments from 12 companies in 2025. Trend: 2023 $2,234 · 2024 $1,981 · 2025 $1,845
Food & beverage: $1,845
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 19 | $387 |
| E.R. Squibb & Sons, L.L.C. | 13 | $320 |
| Teva Pharmaceuticals USA, Inc. | 19 | $264 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $261 |
| Neurocrine BioSciences, Inc. | 10 | $173 |
| Alkermes, Inc. | 5 | $105 |
| Lundbeck LLC | 3 | $77 |
| ABBVIE INC. | 4 | $76 |
| Janssen Pharmaceuticals, Inc | 4 | $61 |
| Axsome Therapeutics, Inc. | 2 | $56 |
Products named: COBENFY, CAPLYTA, REXULTI, ABILIFY MAINTENA, INGREZZA, UZEDY, AUSTEDO XR, ARISTADA.
Industry payments across GA — which companies pay providers there.
